Intima’s public neoantigen discovery platform; plus MS autoantigens and more

Memorial Sloan Kettering Cancer Center researchers, including Smita Chandran and Christopher Klebanoff, combined high-throughput single-cell transcriptomic and TCR sequencing and found an immunogenic public neoantigen that arises from mutant PIK3CA. Published in Nature Medicine, adoptive transfer of TCR-engineered T cells reduced tumors and enhanced survival in mice bearing PIK3CA-mutant tumors compared with mice that received a control TCR or mice with wild type PIK3CA tumors.

The TCR discovery platform and the PIK3CA public neoantigen TCRs were licensed to Intima Bioscience Inc. last December...